Clinical Trials Related to Marginal Zone Lymphoma

Related studies linked through entity extraction aliases.

Lenalidomide and R-CHOP in B-cell Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Status: COMPLETED
Phase: PHASE1

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.

Status: COMPLETED
Phase: PHASE3

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

Status: TERMINATED
Phase: NA

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Status: COMPLETED
Phase: PHASE2

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Status: COMPLETED
Phase: PHASE2

Gemcitabine for Marginal Zone Lymphoma

Status: TERMINATED
Phase: PHASE2